120 related articles for article (PubMed ID: 38230960)
1. Real-World Outcomes of Inoperable and Metastatic Cutaneous Head and Neck Melanoma Patients.
Rozendorn N; Shutan I; Feinmesser G; Grynberg S; Hodadov H; Alon E; Asher N
Laryngoscope; 2024 Jun; 134(6):2762-2770. PubMed ID: 38230960
[TBL] [Abstract][Full Text] [Related]
2. Poor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatment.
Hawkins ML; Rioth MJ; Eguchi MM; Cockburn M
J Am Acad Dermatol; 2019 Jun; 80(6):1640-1649. PubMed ID: 30654077
[TBL] [Abstract][Full Text] [Related]
3. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant treatment for stage III and IV cutaneous melanoma.
Gorry C; McCullagh L; O'Donnell H; Barrett S; Schmitz S; Barry M; Curtin K; Beausang E; Barry R; Coyne I
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012974. PubMed ID: 36648215
[TBL] [Abstract][Full Text] [Related]
5. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
6. Primary Mucosal Melanoma: Clinical Experience from a Single Italian Center.
Falcone R; Verkhovskaia S; Di Pietro FR; Poti G; Samela T; Carbone ML; Morelli MF; Zappalà AR; di Rocco ZC; Morese R; Piesco G; Marchetti P; Failla CM; De Galitiis F
Curr Oncol; 2024 Jan; 31(1):588-597. PubMed ID: 38275835
[TBL] [Abstract][Full Text] [Related]
7. Retrospective multicenter evaluation of patients diagnosed with mucosal melanoma: a study of Anatolian Society of Medical Oncology.
Ercelep O; Topcu TO; Bayoglu IV; Ekinci AS; Koca S; Kavgaci H; Ozcelik M; Alacacioglu A; Uzunoglu S; Bozkurt O; Ulas A; Aksoy A; Taskoylu BY; Gumussay O; Yaman S; Uysal M; Aydin D; Gumus M
Tumour Biol; 2016 Sep; 37(9):12033-12038. PubMed ID: 27173124
[TBL] [Abstract][Full Text] [Related]
8. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
Pontes F; Garcia AR; Domingues I; João Sousa M; Felix R; Amorim C; Salgueiro F; Mariano M; Teixeira M
Cancer Treat Res Commun; 2021; 27():100375. PubMed ID: 33882378
[TBL] [Abstract][Full Text] [Related]
9. Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
[TBL] [Abstract][Full Text] [Related]
10. Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study.
van Zeijl MCT; Haanen JBAG; Wouters MWJM; de Wreede LC; Jochems A; Aarts MJB; van den Berkmortel FWPJ; de Groot JWB; Hospers GAP; Kapiteijn EW; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van der Hoeven KJM; van den Eertwegh AJM
J Immunother; 2020 Oct; 43(8):256-264. PubMed ID: 32804914
[TBL] [Abstract][Full Text] [Related]
11. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of apatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma: a retrospective multi-center study.
Liu Z; Zheng Z; Dong L; Guo X; Jia X; Wang J; Meng L; Cui X; Jiang X
Sci Rep; 2022 Oct; 12(1):18327. PubMed ID: 36316341
[TBL] [Abstract][Full Text] [Related]
13. Primary tumour category, site of metastasis, and baseline serum S100B and LDH are independent prognostic factors for survival in metastatic melanoma patients treated with anti-PD-1.
Janka EA; Ványai B; Szabó IL; Toka-Farkas T; Várvölgyi T; Kapitány A; Szegedi A; Emri G
Front Oncol; 2023; 13():1237643. PubMed ID: 37664072
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma.
Kroeze SGC; Fritz C; Schaule J; Siva S; Kahl KH; Sundahl N; Blanck O; Kaul D; Adebahr S; Verhoeff JJC; Skazikis G; Roeder F; Geier M; Eckert F; Guckenberger M
BJU Int; 2021 Jun; 127(6):703-711. PubMed ID: 33113260
[TBL] [Abstract][Full Text] [Related]
15. Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma.
Zhao B; Zhao H; Zhao J
Int J Cancer; 2019 Jan; 144(1):169-177. PubMed ID: 30121946
[TBL] [Abstract][Full Text] [Related]
16. Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study.
Marconcini R; Fava P; Nuzzo A; Manacorda S; Ferrari M; De Rosa F; De Tursi M; Tanda ET; Consoli F; Minisini A; Pimpinelli N; Morgese F; Bersanelli M; Tucci M; Saponara M; Parisi A; Ocelli M; Bazzurri S; Massaro G; Morganti R; Ciardetti I; Stanganelli I
Front Oncol; 2022; 12():917999. PubMed ID: 36046043
[TBL] [Abstract][Full Text] [Related]
17. Tumor location predicts survival in cutaneous head and neck melanoma.
Tseng WH; Martinez SR
J Surg Res; 2011 May; 167(2):192-8. PubMed ID: 21176922
[TBL] [Abstract][Full Text] [Related]
18. Results of systemic treatment of cutaneous melanoma in inoperable stage III and IV.
Cybulska-Stopa B; Skoczek M; Ziobro M; Switaj T; Falkowski S; Morysiński T; Hetnał M; Cedrych I; Rutkowski P
Contemp Oncol (Pozn); 2012; 16(6):532-45. PubMed ID: 23788941
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib.
Saiag P; Robert C; Grob JJ; Mortier L; Dereure O; Lebbe C; Mansard S; Grange F; Neidhardt EM; Lesimple T; Machet L; Bedane C; Maillard H; Dalac-Rat S; Nardin C; Szenik A; Denden A; Dutriaux C
Eur J Cancer; 2021 Sep; 154():57-65. PubMed ID: 34243078
[TBL] [Abstract][Full Text] [Related]
20. Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy.
Watson AS; Goutam S; Stukalin I; Ewanchuk BW; Sander M; Meyers DE; Pabani A; Cheung WY; Heng DYC; Cheng T; Monzon JG; Navani V
JAMA Netw Open; 2022 Dec; 5(12):e2245596. PubMed ID: 36480204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
